Patients with CLL prescribed BTK inhibitors may have a higher chance of developing secondary cancers, according to recent research.
Patients with chronic lymphocytic leukemia who take BTK inhibitors tend to have a higher rate of secondary cancers than the general population, explained David A. Bond, MD, an assistant professor at The Ohio State University.
In a study including 691 patients, Bond and his team catalogued secondary cancer instances, and found that these diagnoses were the second leading cause of death in the population.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
July 15th 2024Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.